Literature DB >> 18032109

Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage.

Flavio Moroni1.   

Abstract

Poly(ADP-ribose)polymerases (PARPs) are enzymes that are able to catalyze the transfer of ADP-ribose units from NAD to substrate proteins and are particularly abundant in cell nuclei where they play key roles in the maintenance of genomic integrity, control of cell cycle and gene expression. Brain ischemia overactivates PARPs and PARP-deficient mice or animal treated with PARP inhibitors have a drastically reduced brain damage in various stroke models. PARP 'overactivation' occurs not only in neurons but also in astrocytes, microglial cells, endothelia, and infiltrating leukocytes. The ensuing cell death occurs through various molecular mechanisms: a) excessive ATP use for NAD synthesis and inhibition of mitochondrial function with subsequent energy failure (particularly important in neurons); b) apoptosis-inducing factor (AIF) translocation from the mitochondria to the nucleus (present in neurons, endothelial, and other cells); c) excessive expression of inflammatory mediators (well demonstrated in glial cells) or d) reduced expression of prosurvival factors. Thus PARPs seem to play key roles in postischemic brain damage and are now considered interesting targets for therapies aimed at reducing stroke pathology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032109     DOI: 10.1016/j.coph.2007.10.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  62 in total

Review 1.  Protective effects and mechanisms of sirtuins in the nervous system.

Authors:  Feng Zhang; Suping Wang; Li Gan; Peter S Vosler; Yanqin Gao; Michael J Zigmond; Jun Chen
Journal:  Prog Neurobiol       Date:  2011-09-10       Impact factor: 11.685

2.  Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia.

Authors:  Fei Teng; Ling Zhu; Junhui Su; Xi Zhang; Ning Li; Zhiyu Nie; Lingjing Jin
Journal:  Neurochem Res       Date:  2016-02-11       Impact factor: 3.996

Review 3.  Targeting NAD+ Metabolism to Enhance Radiation Therapy Responses.

Authors:  Joshua E Lewis; Naveen Singh; Reetta J Holmila; Baran D Sumer; Noelle S Williams; Cristina M Furdui; Melissa L Kemp; David A Boothman
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

Review 4.  The DNA-damage response in human biology and disease.

Authors:  Stephen P Jackson; Jiri Bartek
Journal:  Nature       Date:  2009-10-22       Impact factor: 49.962

5.  NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death.

Authors:  Conrad C Alano; Philippe Garnier; Weihai Ying; Youichirou Higashi; Tiina M Kauppinen; Raymond A Swanson
Journal:  J Neurosci       Date:  2010-02-24       Impact factor: 6.167

Review 6.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

Review 7.  Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

Authors:  Frédérique Mégnin-Chanet; Marc A Bollet; Janet Hall
Journal:  Cell Mol Life Sci       Date:  2010-08-20       Impact factor: 9.261

Review 8.  Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease.

Authors:  Rosella Abeti; Michael R Duchen
Journal:  Neurochem Res       Date:  2012-10-18       Impact factor: 3.996

9.  Calpain activation and Na+/Ca2+ exchanger degradation occur downstream of calcium deregulation in hippocampal neurons exposed to excitotoxic glutamate.

Authors:  Tatiana Brustovetsky; Alexey Bolshakov; Nickolay Brustovetsky
Journal:  J Neurosci Res       Date:  2010-05-01       Impact factor: 4.164

10.  PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.

Authors:  Vimal Selvaraj; Mangala M Soundarapandian; Olga Chechneva; Ambrose J Williams; Maxim K Sidorov; Athena M Soulika; David E Pleasure; Wenbin Deng
Journal:  J Biol Chem       Date:  2009-07-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.